普莱柯(603566) - 2025 Q2 - 季度业绩预告

Pricer Biological 2025 Semi-Annual Performance Forecast Analysis Current Period Performance Forecast The company forecasts significant H1 2025 performance growth, with net profit attributable to shareholders expected to increase by 44.70% to 64.98% 2025 Semi-Annual Performance Forecast Details | Performance Indicator | 2025 Semi-Annual Estimate (RMB) | Year-on-Year Growth Rate | | :--- | :--- | :--- | | Net profit attributable to shareholders of the parent company | 107 million yuan - 122 million yuan | 44.70% - 64.98% | | Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses | 93 million yuan - 106 million yuan | 40.05% - 59.63% | - This performance forecast represents preliminary calculations by the company's finance department and has not been audited[3] Prior Period Performance Review In H1 2024, the company reported net profit attributable to shareholders of 73.95 million yuan and non-recurring net profit of 66.40 million yuan 2024 Semi-Annual Key Financial Data | Indicator (H1 2024) | Amount (RMB) | | :--- | :--- | | Net profit attributable to shareholders of the parent company | 73.95 million yuan | | Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses | 66.40 million yuan | | Earnings per share | 0.21 yuan/share | Analysis of Main Reasons for Performance Increase Performance growth is driven by new vaccine product launches, sustained high growth in pet product sales, and optimized marketing and production management - New product launches, including the Porcine Pseudorabies Live Vaccine (HN1201-R1 strain) and Adenovirus Series Poultry Pentavalent Vaccine, contributed new performance growth points[7] - Sales revenue from pet-related products continued to maintain a high growth trend[7] - The company focused on marketing system reform, strengthening process management and performance appraisal to ensure sales target achievement[7] - Unit costs were optimized through lean production management, and sales expense control was strengthened, achieving high-quality and efficient development[7] Risk Warning and Other Notes The company confirms no significant uncertainties in this forecast, reminding investors that these are preliminary figures subject to the final 2025 semi-annual report - The company states there are no significant uncertainties affecting the accuracy of this performance forecast[8] - The above forecast data are preliminary calculations, and investors are advised to be aware of investment risks, with specific financial data subject to the company's officially disclosed 2025 semi-annual report[9]